Targeting and therapeutic peptide-based strategies for polycystic kidney disease.

摘要: Abstract Polycystic kidney disease (PKD) is characterized by progressive cyst growth and a leading cause of renal failure worldwide. Currently, there are limited therapeutic options available to PKD patients, only one drug, tolvaptan, has been FDA-approved slow progression. Similar other small molecule drugs, however, tolvaptan costly, moderately effective, causes adverse events high patient dropout rates. Peptides may mitigate many drawbacks as they can be highly tissue-specific, biocompatible, economically scaled-up. function targeting ligands that direct therapies diseased tissue, or potent agents themselves. This review discusses various aberrant signaling pathways in receptors potential targets peptide-mediated strategies. Additionally, peptides utilized applications, but prove useful the context PKD, highlighted. Insights into novel peptide-based solutions have improve clinical management provided.